Clinical trials: Drug Drug Interaction (DDI)
Infection, Human Immunodeficiency Virus
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no…
- Trial name
- NCT02480894
- Testing
- BMS-663068, Maraviroc
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Adult Participants
A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)
The purpose of the study is to learn how itraconazole changes how the body processes the study medicine called PF-07248144. The study will also look at the safety, tolerability, and how PF-07248144 is changed and removed from the…
- Trial name
- NCT07335419
- Testing
- PF-07248144, Itraconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Healthy
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ASC40 in healthy volunteers.
- Trial name
- NCT04843449
- Testing
- ASC40, Itraconazole, rifampicin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Sarcoma, Kaposi, HIV Infections
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Primary: To evaluate the safety, toxicity, and antitumor activity of two doses of interferon alfa-2b (IFN-alpha) combined with a fixed dose of didanosine (ddI) in patients with Kaposi's sarcoma associated with HIV infection.
- Trial name
- NCT00001114
- Testing
- Interferon alfa-2b, Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin
This is a study of a drug drug interaction between Supaglutide and Digoxin or Metformin.
- Trial name
- NCT05694221
- Testing
- Supaglutide injection, Digoxin, Metformin
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
AMG 386 Drug-Drug Interaction Study With Paclitaxel
The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel
- Trial name
- NCT01992341
- Testing
- AMG 386, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Amgen
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Drug-Drug Interactions of JMKX003142 in Healthy Participants
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.
- Trial name
- NCT07565441
- Testing
- JMKX003142 tablets, Fluconazole Capsules, Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
Drug-Drug Interaction Study of Voriconazole With Clarithromycin.
The current study evaluated the Pharmacokinetic (PK) drug-drug interaction (PK-DDI) of voriconazole with clarithromycin in healthy male volunteers.
- Trial name
- NCT05380245
- Testing
- Voriconazole 200 mg x 2 Tablets, Clarithromycin 500 mg x 1Tablets
- Where
- Pakistan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Abdul Wali Khan University Mardan
NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies
- Trial name
- NCT07704658
- Testing
- Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Rigel Pharmaceuticals
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Healthy Volunteers
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
- Trial name
- NCT06250205
- Testing
- Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NewAmsterdam Pharma
Pharmacokinetics, DDI (Drug-Drug Interaction)
A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects
The purpose of this study to explore the effect of multiple oral doses of itraconazole on the pharmacokinetics of a single oral dose of ASP1707 in healthy female subjects.
- Conditions
- Pharmacokinetics, DDI (Drug-Drug Interaction), Healthy Subjects
- Trial name
- NCT02175407
- Testing
- ASP1707, itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
gemigliptin,SGLT-2i DDI study
- Trial name
- NCT03565458
- Testing
- Gemigliptin, Dapagliflozin, Empagliflozin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Infection, Human Immunodeficiency Virus
Drug-drug Interaction (DDI) Rifabutin
The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes
- Trial name
- NCT02138084
- Testing
- BMS-663068, Rifabutin, Ritonavir
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Drug Interaction
DDI Study Between Dorzagliatin and Rifampicin
The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.
- Trial name
- NCT04080609
- Testing
- Dorzagliatin
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of…
- Trial name
- NCT03376529
- Testing
- SPR741, Ceftazidime, Piperacillin/tazobactam
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Healthy Volunteers
Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects
Study of a drug drug interaction between Paroxetine and PF-00299804.
- Trial name
- NCT01318031
- Testing
- Period 1, Period 2
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Tract Infections, HIV Infections
Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)
Single-arm, single-center, Phase I/II clinical trial, in four groups. Individuals with HIV infection taking Efavirenz (EFV) and two nucleoside reverse transcriptase inhibitors (NRTI) who have undetectable (Groups 1 and 2) or…
- Trial name
- IMPAACT4TB (NCT03435146)
- Testing
- 3HP plus DTG +2NRTIs
- Where
- South Africa
- Volunteers
- 135 people
- Sponsor
- The Aurum Institute NPC